Monthly migraine days, acute medication use days, and migraine-specific quality of life in responders to atogepant: A post hoc analysis

被引：0

作者：

Dodick, D. W. ^{[1
]}

Lipton, R. B. ^{[2
]}

Nahas, S. J. ^{[3
]}

Pozo-Rosich, P. ^{[4
]}

McAllister, P. ^{[5
]}

Mechtler, L. L. ^{[6
]}

Ma, J. ^{[7
]}

Dabruzzo, B. L. ^{[7
]}

Dufek, M. ^{[8
]}

Severt, L. ^{[8
]}

Finnegan, M. ^{[9
]}

Trugman, J. M. ^{[8
]}

机构：

[1] Mayo Clin, Dept Neurol, Scottsdale, AZ USA

[2] Albert Einstein Coll Med, Bronx, NY 10467 USA

[3] Thomas Jefferson Univ, Philadelphia, PA 19107 USA

[4] Vall Hebron Univ Hosp & Inst Res, Dept Neurol, Headache Unit, Barcelona, Spain

[5] New England Inst Neurol Headache, Stamford, CT USA

[6] Dent Neurol Inst, Buffalo, NY USA

[7] AbbVie Inc, Madison, NJ USA

[8] AbbVie, Madison, NJ USA

[9] AbbVie Inc, Madison, NJ USA

来源：

HEADACHE | 2022年 / 62卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P-182

引用

页码：152 / 153

页数：2

共 50 条

[1] Monthly Migraine Days, Acute Medication Use Days, and Migraine-Specific Quality of Life in Responders to Atogepant: A Post Hoc Analysis
Dodick, D.
Lipton, R.
Nahas, S.
Pozo-Rosich, P.
McAllister, P.
Mechtler, L.
Ma, J.
Dabruzzo, B.
Dufek, M.
Severt, L.
Finnegan, M.
Trugman, J.
JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
[2] ATOGEPANT SIGNIFICANTLY REDUCES MEAN MONTHLY MIGRAINE DAYS IN THE PHASE 3 TRIAL (ADVANCE) FOR THE PREVENTION OF MIGRAINE
Ailani, Jessica
Lipton, Richard B.
Goadsby, Peter J.
Guo, Hua
Miceli, Rosa
Severt, Lawrence
Finnegan, Michelle
Trugman, Joel M.
CEPHALALGIA, 2020, 40 : 15 - 16
[3] Atogepant Significantly Reduces Mean Monthly Migraine Days in the Phase 3 Trial (ADVANCE) for the Prevention of Migraine
Ailani, J.
Lipton, R. B.
Goadsby, P. J.
Guo, H.
Miceli, R.
Severt, L.
Finnegan, M.
Trugman, J. M.
JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 107 - 108
[4] Determinants of migraine-specific quality of life
Santanello, N
Davies, G
Allen, C
Kramer, M
Lipton, R
CEPHALALGIA, 2002, 22 (08) : 680 - 685
[5] Atogepant Significantly Reduces Mean Monthly Migraine Days in the Phase 3 Trial (ADVANCE) for the Prevention of Migraine
Ailani, J.
Lipton, R. B.
Goadsby, P. J.
Guo, H.
Miceli, R.
Severt, L.
Finnegan, M.
Trugman, J. M.
CEPHALALGIA, 2021, 41 (1_SUPPL) : 160 - 160
[6] Daily atogepant for the preventive treatment of migraine increases responder rates for reduction in mean monthly migraine days
Lipton, R. B.
Pozo-Rosich, P.
Blumenfeld, A. M.
Dodick, D. W.
McAllister, P.
Li, Y.
Lu, K.
Dabruzzo, B.
Miceli, R.
Severt, L.
Finnegan, M.
Trugman, J. M.
HEADACHE, 2021, 61 : 118 - 118
[7] Effect of galcanezumab on migraine headache days in women with menstrual migraine: A post hoc analysis
MacGregor, E.
Okonkwo, R.
Fernandes, M. F.
Rettiganti, M.
Detke, H.
Pavlovic, J. M.
HEADACHE, 2021, 61 : 87 - 88
[8] Migraine-specific quality of life questionnaire and relapse of medication overuse headache
Stefano Caproni
Elisa Bianchi
Letizia M. Cupini
Ilenia Corbelli
Ettore Beghi
Paolo Calabresi
Paola Sarchielli
BMC Neurology, 15
[9] Migraine-specific quality of life questionnaire and relapse of medication overuse headache
Caproni, Stefano
Bianchi, Elisa
Cupini, Letizia M.
Corbelli, Ilenia
Beghi, Ettore
Calabresi, Paolo
Sarchielli, Paola
BMC NEUROLOGY, 2015, 15
[10] Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials
Tepper, Stewart J.
Ashina, Messoud
Reuter, Uwe
Hallstroem, Yngve
Broessner, Gregor
Bonner, Jo H.
Picard, Hernan
Cheng, Sunfa
Chou, Denise E.
Zhang, Feng
Klatt, Jan
Mikol, Daniel D.
JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):

← 1 2 3 4 5 →